secwatch.observer — SEC 8-K summary
======================================

Issuer:     INOVIO PHARMACEUTICALS, INC. (INO)
CIK:        0001055726
Form:       8-K
Filed at:   2023-05-10T23:59:59+00:00
Accession:  0001193125-23-140755
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INOVIO Q1 2023 net loss $40.6M; VGX-3100 misses in biomarker population
-----------------------------------------------------------------------

- Net loss $40.6M ($0.16/sh) vs $79.1M ($0.36) in Q1 2022; revenue $115K vs $199K.
- Cash and equivalents $223.8M as of March 31; runway projected into Q1 2025.
- Phase 3 VGX-3100 for cervical HSIL missed primary endpoint in biomarker population but achieved statistical significance in all-participants.
- INO-3107 for RRP: 10 of 11 (91%) patients saw reduction in surgical interventions; well-tolerated.
- Appointed Dr. Cheryl Elder as SVP Regulatory Affairs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523140755/0001193125-23-140755-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1055726/000119312523140755/d425606d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-140755

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer